Studies have shown that genetic heterogeneity of HCC, tumor microenvironment, changes in PI3K/AKT pathway, epithelial–mesenchymal transition (EMT), autophagy activation, and other factors can affect the resistance of HCC cells to sorafenib [6, 7]. Here, AKT1 is linked to hepatocellular carcinoma.